Finn Børlum Kristensen1, Kristian Lampe2, Claudia Wild3, Marina Cerbo4, Wim Goettsch5, Lidia Becla6. 1. Danish Health Authority, Copenhagen, Denmark; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. Electronic address: fbk@dadlnet.dk. 2. National Institute of Health and Welfare, Helsinki, Finland. 3. Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria. 4. The National Agency for Regional Health Services (Agenas), Rome, Italy. 5. Dutch National Health Care Institute (ZIN), Diemen, The Netherlands; Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, The Netherlands. 6. Danish Health Authority, Copenhagen, Denmark.
Abstract
BACKGROUND AND OBJECTIVES: The HTA Core Model® as a science-based framework for assessing dimensions of value was developed as a part of the European network for Health Technology Assessment project in the period 2006 to 2008 to facilitate production and sharing of health technology assessment (HTA) information, such as evidence on efficacy and effectiveness and patient aspects, to inform decisions. METHODS: It covers clinical value as well as organizational, economic, and patient aspects of technologies and has been field-tested in two consecutive joint actions in the period 2010 to 2016. A large number of HTA institutions were involved in the work. RESULTS: The model has undergone revisions and improvement after iterations of piloting and can be used in a local, national, or international context to produce structured HTA information that can be taken forward by users into their own frameworks to fit their specific needs when informing decisions on technology. The model has a broad scope and offers a common ground to various stakeholders through offering a standard structure and a transparent set of proposed HTA questions. It consists of three main components: 1) the HTA ontology, 2) methodological guidance, and 3) a common reporting structure. It covers domains such as effectiveness, safety, and economics, and also includes domains covering organizational, patient, social, and legal aspects. There is a full model and a focused rapid relative effectiveness assessment model, and a third joint action is to continue till 2020. CONCLUSION: The HTA Core Model is now available for everyone around the world as a framework for assessing value.
BACKGROUND AND OBJECTIVES: The HTA Core Model® as a science-based framework for assessing dimensions of value was developed as a part of the European network for Health Technology Assessment project in the period 2006 to 2008 to facilitate production and sharing of health technology assessment (HTA) information, such as evidence on efficacy and effectiveness and patient aspects, to inform decisions. METHODS: It covers clinical value as well as organizational, economic, and patient aspects of technologies and has been field-tested in two consecutive joint actions in the period 2010 to 2016. A large number of HTA institutions were involved in the work. RESULTS: The model has undergone revisions and improvement after iterations of piloting and can be used in a local, national, or international context to produce structured HTA information that can be taken forward by users into their own frameworks to fit their specific needs when informing decisions on technology. The model has a broad scope and offers a common ground to various stakeholders through offering a standard structure and a transparent set of proposed HTA questions. It consists of three main components: 1) the HTA ontology, 2) methodological guidance, and 3) a common reporting structure. It covers domains such as effectiveness, safety, and economics, and also includes domains covering organizational, patient, social, and legal aspects. There is a full model and a focused rapid relative effectiveness assessment model, and a third joint action is to continue till 2020. CONCLUSION: The HTA Core Model is now available for everyone around the world as a framework for assessing value.
Authors: Hassane Alami; Pascale Lehoux; Yannick Auclair; Michèle de Guise; Marie-Pierre Gagnon; James Shaw; Denis Roy; Richard Fleet; Mohamed Ali Ag Ahmed; Jean-Paul Fortin Journal: J Med Internet Res Date: 2020-07-07 Impact factor: 5.428
Authors: Erica Pitini; Valentina Baccolini; Giuseppe Migliara; Claudia Isonne; Alessandro Sindoni; Elena Mazzalai; Federica Turatto; Corrado De Vito; Carolina Marzuillo; Paolo Villari Journal: Front Public Health Date: 2021-12-06